PYCR2

Across TCGA pan-cancer cohorts, PYCR2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYCR2 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PYCR2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PYCR2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where PYCR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.461	1.000	.003	46	view →
PDAC	OS	Quartile	All	0.401	0.631	.015	15	view →
LUAD	OS	Median	II,III,IV	0.815	0.426	.015	4	view →
GBM	DFS	Tertile	All	0.754	0.896	.021	3	view →
HNSC	OS	Quartile	All	0.647	0.852	.034	2	view →
LSCC	OS	Median	All	0.841	0.920	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYCR2–CCRCC (OS)

Open the CCRCC breakdown →